Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
NCT02544152 · Sucampo Pharma Americas, LLC · PHASE2 · terminated · last registry update 2019-12-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Sucampo Pharma Americas, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CLCN2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-20Also stopped (terminated): University of South Alabama, lubiprostone + Matched placebo (NCT01096290)
- 2020-09-09Results posted on the registry: University of South Alabama, lubiprostone + Matched placebo (NCT01096290)
- 2020-07-21Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT02042183)
- 2020-06-25Results posted on the registry: Braintree Laboratories, BLI400 Laxative + Lubiprostone (NCT02481947)
- 2020-05-15Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone (NCT02766777)
- 2020-03-09Results posted on the registry: Sucampo Pharma Americas, LLC, Cohort 1: Lubiprostone Capsule, Fasted + Cohort 1: Lubiprostone Sprinkle Formulation, Fasted (NCT03010631)
- 2020-01-21Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone (NCT02138136)
- 2020-01-14Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT03097861)
- 2019-12-30Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone 24 (NCT00620061)
- 2019-12-26Results posted on the registry: Sucampo Pharma Americas, LLC, Cobiprostone + Placebo (NCT00597818)
- 2019-12-24Results posted on the registry: Sucampo Pharma Americas, LLC, Lubiprostone + Placebo (NCT01298219)
- 2019-12-13Results posted on the registry: Mallinckrodt, Lubiprostone + Placebo (NCT01993875)
- 2019-12-02Also stopped (terminated): Sucampo Pharma Americas, LLC, Cobiprostone + Placebo (NCT02542215)
- 2019-11-18Also stopped (terminated): Sucampo Pharma Americas, LLC, Placebo + Cobiprostone (NCT00737594)
- 2019-04-01Results posted on the registry: Takeda, Lubiprostone + Placebo (NCT02729909)
- 2019-01-15Results posted on the registry: Augusta University, Lubiprostone + Lubiprostone Control (NCT01190020)
- 2018-12-31Results posted on the registry: Takeda, Placebo + Lubiprostone (NCT02695719)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision